Article Information
History
- July 25, 2021.
Article Versions
- You are currently viewing Version 1 of this article (July 25, 2021 - 20:19).
- Version 2 (August 18, 2021 - 13:18).
- View Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Rajan Ravichandran1,
- Surapaneni Krishna Mohan2,
- Suresh Kumar Sukumaran3,
- Devakumar Kamaraj4,
- Sumetha Suga Daivasuga5,
- Samson Oliver Abraham Samuel Ravi6,
- Sivakumar Vijayaraghavalu7 and
- Ramarathnam Krishna Kumar8,*
- 1Department of Nephrology, MIOT International, Chennai 600089, India and Adjunct Faculty, Indian Institute of Technology Madras (IITM), Chennai 600036, Tamil Nadu (TN), India
- 2Departments of Biochemistry, Molecular Virology & Research, Panimalar Medical College Hospital & Research Institute, Chennai 600123, TN, India
- 3Department of General Medicine, Panimalar Medical College Hospital & Research Institute, Chennai 600123, TN, India
- 4Departments of Pharmacology & Research, Panimalar Medical College Hospital & Research Institute, Chennai 600123, TN, India
- 5Departments of Microbiology & Molecular Virology, Panimalar Medical College Hospital & Research Institute, Chennai 600123, TN, India
- 6Molbio Diagnostics Private Limited, Verna Industrial Estate, Verna, Goa - 403 722, India
- 7Narayana Translational Research and Incubation Center, Narayana Medical College, Nellore 524003, Andhra Pradesh, India and Adjunct Faculty, IITM, Chennai 600036, TN, India
- 8Department of Engineering Design, IITM, Chennai 600036, TN, India
- ↵*Corresponding Author Professor R. Krishna Kumar
, Department of Engineering Design, Indian Institute of Technology Madras, Chennai 600036, Tamil Nadu, India. E-mail: rkkumar{at}iitm.ac.in
Posted July 25, 2021.
Use of Indomethacin for mild and moderate Covid -19 patients A Randomized Control Trial
